The effectiveness of botulinum A injection in the treatment of premature ejaculation patients

Investigating the effectiveness of botulinum A subdermal injection in the treatment of patients with premature ejaculation resistant to treatment: a clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190624043991N23

Enrollment

Registered

2023-12-07

Start date

2024-03-16

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premature ejaculation in patients. Premature ejaculation

Interventions

Intervention 1: Intervention group: Injection of 100 units of botulinum toxin-A with a concentration of 100 units/ml under the skin of the glans region: 15 patients. Intervention 2: Control group: Inj

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Informed consent from patients Having treatment-resistant premature ejaculation

Exclusion criteria

Exclusion criteria: Other sexual diseases such as erectile dysfunction and decreased libido Any skin disease and genital infection History of allergy to injectable drugs Injection drug addicts or any type of drug addiction Patients who are withdrawing from drugs

Design outcomes

Primary

Measure	Time frame
Intravaginal ejaculation latency. Timepoint: Before and 4 weeks after injection. Method of measurement: Premature ejaculation diagnosis questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Akram Mirzaei

Tehran University of Medical Sciences

mirzaee.scholar@gmail.com+98 21 6634 8560

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026